Results 11 to 20 of about 2,738 (166)

Familial Hypercholesterolemia and Lipoprotein Apheresis. [PDF]

J Atheroscler Thromb, 2019
Lipoprotein apheresis has been developed as the treatment for refractory familial hypercholesterolemia (FH) to remove low-density lipoprotein (LDL), which is the main pathogenic factor. Currently, three procedures are available in Japan, including the plasma exchange, double-membrane filtration, and selective LDL adsorption.
Makino H, Koezuka R, Tamanaha T, Ogura M, Matsuki K, Hosoda K, Harada-Shiba M.   +6 more
europepmc   +5 more sources

Treating PAD Patients with Lipoprotein Apheresis. [PDF]

J Atheroscler Thromb
Harada-Shiba M.
europepmc   +3 more sources

Role of lipoprotein apheresis in the management of familial hypercholesterolemia

Global Journal of Transfusion Medicine, 2021
Familial Hypercholesterolemia (FH) is an autosomal dominant disorder due to a congenital absence of low-density lipoprotein receptor (LDL-R) that transports cholesterol-carrying lipoprotein particles into cells.
Shamanna Seshadri Iyengar, Ambuja Kantharaj, Chandrashekar Shivaram, D S Hemantha Kumara, Roopa Murgod, G Shreedhara   +5 more
doaj   +1 more source

Lipoprotein(a) Lowering-From Lipoprotein Apheresis to Antisense Oligonucleotide Approach. [PDF]

J Clin Med, 2020
It is well-known that elevated lipoprotein(a)—Lp(a)—levels are associated with a higher risk of cardiovascular (CV) mortality and all-cause mortality, although a standard pharmacotherapeutic approach is still undefined for patients with high CV risk dependent on hyperlipoproteinemia(a). Combined with high Lp(a) levels, familial hypercholesterolemia (FH)
Greco MF, Sirtori CR, Corsini A, Ezhov M, Sampietro T, Ruscica M.   +5 more
europepmc   +5 more sources

Therapeutic apheresis in kidney diseases: an updated review

Renal Failure, 2022
Besides conventional medical therapies, therapeutic apheresis has become an important adjunctive or alternative therapeutic option to immunosuppressive agents for primary or secondary kidney diseases and kidney transplantation.
Yi-Yuan Chen, Xin Sun, Wei Huang, Fang-Fang He, Chun Zhang   +4 more
doaj   +1 more source

Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia

Journal of Lipid Research, 1997
Apheresis only partially controls raised low density lipoprotein cholesterol levels in patients with homozygous familial hypercholesterolemia, who usually respond poorly to lipid-lowering drugs.
A D Marais, R P Naoumova, J C Firth, C Penny, C K Neuwirth, G R Thompson   +5 more
doaj   +1 more source

Modern Approaches to Lower Lipoprotein(a) Concentrations and Consequences for Cardiovascular Diseases

Biomedicines, 2021
Lipoprotein(a) (Lp(a)) is a low density lipoprotein particle that is associated with poor cardiovascular prognosis due to pro-atherogenic, pro-thrombotic, pro-inflammatory and pro-oxidative properties.
Victoria A. Korneva, Tatjana Yurjevna Kuznetsova, Ulrich Julius   +2 more
doaj   +1 more source

Lipoprotein turnover and possible remnant accumulation in preeclampsia: insights from the Freiburg Preeclampsia H.E.L.P.-apheresis study

Lipids in Health and Disease, 2018
Background Preeclampsia is a life-threatening disease in pregnancy, and its complex pathomechanisms are poorly understood. In preeclampsia, lipid metabolism is substantially altered.
Christine Contini, Martin Jansen, Brigitte König, Filiz Markfeld-Erol, Mirjam Kunze, Stefan Zschiedrich, Ulrich Massing, Irmgard Merfort, Heinrich Prömpeler, Ulrich Pecks, Karl Winkler, Gerhard Pütz   +11 more
doaj   +1 more source

Lipoprotein glomerulopathy treated with LDL-apheresis (Heparin-induced Extracorporeal Lipoprotein Precipitation system): a case report

Journal of Medical Case Reports, 2009
Introduction Lipoprotein glomerulopathy is a glomerulonephritis which was described for the first time by Saito in 1989 and is currently acknowledged as a separate nosological entity.
Rivasi Paolo, Romano Nicola, Magistroni Riccardo, Leonelli Marco, Furci Luciana, Russi Gianpaolo, Albertazzi Alberto   +6 more
doaj   +1 more source

Acute effects of low density lipoprotein apheresis on metabolic parameters of apolipoprotein B

Journal of Lipid Research, 2000
Apheresis is a treatment option for patients with severe hypercholesterolemia and coronary artery disease. It is unknown whether such therapy changes kinetic parameters of lipoprotein metabolism, such as apolipoprotein B (apoB) secretion rates ...
Klaus G. Parhofer, P. Hugh R. Barrett, Thomas Demant, Peter Schwandt   +3 more
doaj   +1 more source